Legal Representation
Attorney
Jeffrey H. Kaufman
USPTO Deadlines
Application History
11 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Dec 16, 2010 | ABN2 | O | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | Loading... |
| Dec 16, 2010 | MAB2 | O | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | Loading... |
| May 20, 2010 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| May 20, 2010 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| May 20, 2010 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| May 17, 2010 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Mar 17, 2010 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Mar 17, 2010 | AMPX | O | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | Loading... |
| Mar 3, 2010 | PARI | I | TEAS VOLUNTARY AMENDMENT RECEIVED | Loading... |
| Feb 18, 2010 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Feb 16, 2010 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations used for the treatment of cancer, pharmaceutical preparations administered as a radiosensitizer and used for the treatment of cancer, pharmaceutical preparations used for the treatment of urological diseases, pharmaceutical preparations used for the treatment of hormonal disorders, peptides-containing pharmaceutical preparations used for hormonal and tumors treatments, pharmaceutical preparations used for the treatment of endocrine diseases, pharmaceutical preparations used for the treatment of carcinoid tumors, pharmaceutical preparations used for the treatment of age-related diseases, pharmaceutical preparation used for the treatment of endometriosis, pharmaceutical preparations used for the treatment of uterine myoma, pharmaceutical preparations used for the treatment of non-malignant tumors, pharmaceutical preparation used for the treatment for begnin prostatic hyperplasia (BPH), pharmaceutical preparations used as a tubulin inhibitor, pharmaceutical preparations based on LHRH antagonists platform, pharmaceutical preparations based on angiogenesis inhibitors platform, pharmaceutical preparations used to induce apoptosis
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005